Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Dermatologic 5Sarcoma 1

Conditions

Sarcoma 1341Glioblastoma 493Gliosarcoma 470Osteosarcoma 364Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 252Neoplasms 231Glioma 230Lymphoma 227Rhabdomyosarcoma 209Neuroblastoma 209Breast Neoplasms 205Sarcoma, Ewing 203Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 183Ovarian Neoplasms 177Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 169Lymphoma, Follicular 158Liposarcoma 144Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphomatoid Papulosis × Sarcoma × Clear all
NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡